In this episode of The BioPharm Brief, we cover the FDA approval of Lupin's interchangeable ranibizumab biosimilar Ranluspec, a new iPSC cell therapy manufacturing partnership between Made Scientific and Pluristyx, and emerging research on TIGIT as a potential immunotherapy target in pancreatic cancer.
Today's biopharmaceutical news highlights an FDA breakthrough designation in spinal muscular atrophy, an expanded oncology collaboration focused on tumor activated bispecifics, and a new biosimilar launch for retinal diseases in Europe.
Daily biopharma update covering RNA exon editing licensing, gene therapy clinical data, and preclinical rare disease collaboration advances across the biotech sector.
Today’s BioPharm Brief covers FDA draft guidance aimed at streamlining rare disease gene therapy development, Phase 3 trial updates involving dual survival endpoints in oncology programs, and Eli Lilly’s $1.2 billion licensing deal for a GLP-2 therapy in short bowel syndrome.
New data in lung cancer and solid tumors highlight the growing impact of next-generation immunotherapies, including bispecific antibodies and TCR-based therapies, as developers report encouraging efficacy across difficult-to-treat patient populations.
Pfizer’s $10.5 billion oncology collaboration with Innovent, early clinical progress for a novel PD-1/IL-2 fusion protein, and promising Phase III hepatitis B cure data highlight today’s key developments in biopharmaceutical innovation.
Olezarsen’s latest pancreatitis data, Apogee’s advancing atopic dermatitis program, and Jade Biosciences’ first-in-human autoimmune trial highlight continued momentum in RNA therapeutics, immunology, and antibody development across the biopharmaceutical industry.
Today’s BioPharm Brief covers promising Phase 1 data for Eli Lilly’s gene-editing therapy VERVE-102, evolving CAR-T and bispecific competition in multiple myeloma, and new preclinical findings for a Parkinson’s disease regenerative therapy candidate.
Today’s BioPharm Brief covers major developments in oncology, rare disease therapeutics, and ADC manufacturing, including positive Phase 3 data for Kelun-Biotech’s sac-TMT in triple-negative breast cancer, promising hypochondroplasia results for vosoritide, and new perspectives on risk-based cleaning validation for highly potent drug manufacturing.
This edition of The BioPharm Brief highlights major advances in obesity, oncology, and regenerative medicine, including Merck’s Phase 3 ADC study in metastatic colorectal cancer, Eli Lilly’s promising retatrutide obesity trial results, and manufacturing progress supporting Klotho cell therapy development. Together, these updates reflect the biopharma industry’s accelerating focus on targeted therapies, next-generation weight loss drugs, and scalable cell therapy innovation.
New clinical trial updates highlight advances in RNA editing for alpha-1 antitrypsin deficiency, semaglutide data in MASH liver disease, and improved joint outcomes in psoriatic arthritis treatment comparisons.
Today’s BioPharm Brief covers how biopharma companies are leveraging next-generation platform technologies—from CNS-targeted gene therapy and AI-driven R&D to antibody-cleaving biologics partnerships—to improve therapeutic precision, reduce development barriers, and expand access to advanced medicines.
Today’s BioPharm Brief covers major developments in antibody-drug conjugates, early-stage HER2-positive breast cancer treatment, and the expanding biosimilars market.
AstraZeneca reported encouraging bladder cancer data for Imfinzi plus BCG, Imviva shared early remission findings for allogeneic CAR-T therapy in lupus, and Biogen expanded its rare disease pipeline through its acquisition of Apellis Pharmaceuticals.
Today’s BioPharm Brief covers Phase III clinical trial advances in bladder cancer from AstraZeneca , new in vivo CAR-T financing from Create Medicines, and positive Duchenne muscular dystrophy gene therapy results from REGENXBIO.
Today’s BioPharm Brief covers a major gene therapy milestone, an FDA Breakthrough Therapy designation in rare cancer, and a multi-billion-dollar oncology partnership shaping global drug development pipelines.
Today’s podcast recaps news centered on FcRn modulation, biomarker-guided therapies, and accelerated ADC pathways, which all highlight precision-focused strategies for high-unmet-need diseases.
Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson & Johnson’s dual-pathway approach to inflammatory bowel disease treatment.
Today’s BioPharm Brief covers promising AML remission data from Aptevo, encouraging Duchenne muscular dystrophy trial results from Entrada Therapeutics, and a new GSK licensing deal expanding cardiometabolic RNA therapy development.
Biopharma news today highlights precision MASH therapies, emerging immuno-oncology platforms, and major U.S. manufacturing investments reshaping drug development and supply chains.
Phase III data in thyroid eye disease, long-term ulcerative colitis outcomes, and Crohn disease advances highlight continued momentum in biologics and immunology innovation.
FDA approvals, biotech acquisitions, and clinical trial updates are shaping today’s biopharma landscape. This episode of The BioPharm Brief covers the first approved PROTAC therapy for breast cancer, UCB’s planned acquisition of Candid Therapeutics, and new clinical data from Takeda Pharmaceutical Company in primary immunodeficiency.
In today’s podcast, we're seeing microbiome therapies gain FDA Fast Track status, Leo Pharma expand into gene therapy via acquisition, and automation improving AAV manufacturing efficiency.
In today’s podcast, we see clinical durability, targeted combination strategies, and domestic production investment highlighting integrated approaches to meeting rising global demand for complex therapies.
Survodutide delivers significant Phase III weight loss results, FDA grants RMAT status to Orca-Q, and Ligand expands its portfolio with a $739 million acquisition of XOMA.
Biopharma news highlights: Henlius and Organon gain EU approval for a pertuzumab biosimilar, while Pfizer reports Phase 3 success for Elrexfio in multiple myeloma. Genexine advances GX-BP1 targeting SOX2, signaling new progress in overcoming cancer resistance and expanding oncology innovation.
The BioPharm Brief covers three recent FDA developments shaping the autoimmune and inflammatory disease landscape. The agency cleared a subcutaneous autoinjector for anifrolumab in systemic lupus erythematosus, enabling at-home administration. It also granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia, highlighting its potential as a targeted treatment for a rare condition. In addition, a supplemental application has been submitted for subcutaneous risankizumab as an induction therapy in Crohn disease, which could reduce the need for infusion-based initiation. Together, these updates reflect a growing focus on patient convenience, expanded access, and more precise treatment approaches in immune-mediated diseases.
This episode of The BioPharm Brief covers innovation trends in biopharma hubs, a positive CHMP opinion for Novartis’ intrathecal gene therapy in spinal muscular atrophy, and early clinical data for a novel bispecific ADC in breast cancer. Key updates highlight regulatory momentum, emerging technologies, and next-generation oncology therapeutics.
In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.
New developments in CAR-T therapy, pediatric biologics, and oral GLP-1 treatments highlight expanding innovation across oncology, immunology, and metabolic disease. Early data and regulatory progress signal a shift toward more targeted and accessible therapies for underserved patient populations.
